Clonal hematopoiesis (CH) is an age-related, asymptomatic condition in  which leukemia-associated somatic mutations are detected in the blood of  individuals without a hematologic malignancy. In the nontransplant  setting, CH is uniformly associated with adverse outcomes, including an  elevated risk of developing hematologic malignancies and an increased  risk of nonhematologic outcomes because of altered inflammatory  signaling.  Current evidence has thus been insufficient to resolve  disagreement about whether to screen older candidate donors for CH, and  some transplant centers have begun excluding donors found to have CH on  the basis of the assumption that the adverse associations of native CH  also apply in the context of transplant. This study performed a  comprehensive analysis of samples from donors age 40 years or older to  determine the impact of CH on overall recipient outcomes, risk of DCL,  and measures of graft alloimmune activity.  Article: https://ascopubs.org/doi/full/10.1200/JCO.21.02286